TLSC702

Overview

TLSC702 is a human glyoxalase I ( hGLO I ) inhibitor with an IC 50 of 2.0 μM. TLSC702 inhibits the activity of human glyoxalase I, thereby leading to the accumulation of methylglyoxal and its derived advanced glycation end products. TLSC702 inhibits tumor cell proliferation, induces apoptotic morphological changes, internucleosomal DNA fragmentation and PARP cleavage in tumor cells. TLSC702 can be used in research related to leukemia and lung cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Glyoxalase (GLO) | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > PARP

Product Information

• Catalog No.: HY-117208
• CAS No.: 748786-57-4
• Molecular Formula: C18H15NO3S
• Molecular Weight: 325.38
• Purity: 95.61%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1.25 mg/mL (3.84 mM); Clear solution
• Availability: In-stock

Source

Original product source